Elanco Animal Health Incorporated reported a revenue of $4.715 billion for the fiscal year ending December 31, 2025, marking a 6% increase from $4.439 billion in 2024. The company's gross profit also rose by 6% to $2.593 billion, with a gross margin of 55%. However, Elanco experienced a net loss of $232 million, a significant decline from a net income of $338 million in the previous year, primarily due to increased restructuring charges and the absence of a prior year gain from the divestiture of its aqua business.
The company undertook a restructuring plan in December 2025, which is expected to result in a global headcount reduction of approximately 300 employees and the closure of certain facilities, including its animal studies R&D facility in Monheim, Germany, and a manufacturing site in Kansas City, Kansas. The restructuring is anticipated to yield savings of about $25 million in 2026 and $60 million in 2027. Additionally, Elanco's research and development expenses increased by 7% to $368 million, reflecting higher project costs and employee-related expenses.
Elanco's product portfolio, which includes around 200 brands, saw a notable increase in pet health revenue, which rose by 7% to $2.3 billion, driven by new product launches such as Credelio Quattro and Zenrelia. Farm animal revenue also increased by 5% to $2.362 billion, aided by higher volumes and pricing, although it was partially offset by the impact of the aqua business divestiture. The U.S. remains Elanco's largest market, accounting for 47% of total revenue, with significant contributions from Brazil, the U.K., and China.
Looking ahead, Elanco is focused on expanding its product offerings and geographic reach, particularly in the farm animal sector, following its acquisition of AHV International B.V., which is expected to enhance its portfolio and market presence. The company anticipates continued growth through innovation and strategic investments, despite facing challenges such as regulatory changes and competitive pressures in the animal health industry.
About Elanco Animal Health Inc
Elanco Animal Health Inc. is a global leader in animal health, providing products and services for pets and farm animals. Its portfolio includes parasiticides, vaccines, therapeutics, antibiotics, and feed additives, serving markets worldwide. The company focuses on innovation, portfolio optimization, and sustainability to improve animal well-being, food safety, and environmental impact, supporting farmers, pet owners, and veterinarians across diverse species and regions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.